PGM
VRCA icon

Parian Global Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Parian Global Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,956
Closed -$599K – 53
2021
Q1 		$599K Buy
+3,956
New +$547K 0.27% 31

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parian Global Management's VRCA Position: Q2 2021 in Review

Parian Global Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2021, closing a stake of 3,956 shares — an estimated $599K sold.

Parian Global Management first reported a position in VRCA in Q1 2021 and held it in 1 quarter. The position peaked at $599K in Q1 2021. 53 funds tracked by Wall St. Rank hold VRCA as of Q2 2021.

  • Parian Global Management reported no remaining Verrica Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Parian Global Management sold 3,956 Verrica Pharmaceuticals shares in Q2 2021, an estimated $599K.
  • Parian Global Management first reported a position in Verrica Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Parian Global Management's Verrica Pharmaceuticals position peaked at $599K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2021.

Based on Parian Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.